Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Age: 20 - 75 years old

• Gender: Male or female

• Status: Outpatients

• Mild to moderate essential hypertension

Exclusion Criteria:

• Pregnant women, lactating mothers, women suspected of being pregnant, or women who wish to be pregnant

• Patients with msSBP >==180 mmHg and/or msDBP >=110 mmHg at Visit 1, 2 or 3

• Patients with or suspected of having secondary hypertension (due to aortic coarctation, primary aldosteronism, etc.)

• Patients suspected of having malignant hypertension

Other protocol-defined inclusion/exclusion criteria may apply